NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biotechnology company developing therapies for central nervous system disorders, primarily focusing on psychiatric and pain conditions. The company's pipeline centers on two main drug candidates: NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone in Phase 2 trials for treatment-resistant bipolar depression with acute suicidal ideation, and NRX-100, a preservative-free ketamine formulation for intravenous administration targeting suicidal depression. Both candidates address high-acuity psychiatric conditions with limited existing treatment options.

The company has established partnerships and licensing agreements to support its clinical development and commercialization strategy. NRx holds agreements with Alvogen and Lotus Pharmaceutical for manufacturing and distribution, maintains development arrangements with Glytech and Sarah Herzog Memorial Hospital, and operates a partnership with neurocare Group AG to develop a network of specialized clinics offering integrated neuroplastic care for depression, post-traumatic stress disorder, and other serious mental health conditions.

Incorporated in Delaware with headquarters in Wilmington, the company operates as a pre-revenue clinical-stage entity. With a market capitalization of approximately $0.1 billion, NRx remains dependent on capital markets and partnerships to fund ongoing clinical trials and regulatory activities.